vimarsana.com
Latest Breaking News On - Clinical development at bold therapeutics - Page 1 : vimarsana.com
BOLD-100 and ATR Inhibitors as a New Avenue for PDAC Targeting at AACR 2024
/PRNewswire/ Bold Therapeutics, a clinical-stage biopharmaceutical company at the forefront of developing innovative metallotherapeutics, has announced that.
San-diego
California
United-states
South-korea
Vancouver
British-columbia
Canada
Seoul
Soult-ukpyolsi
E-russell-mcallister
Jim-pankovich
Clinical-development-at-bold-therapeutics
vimarsana © 2020. All Rights Reserved.